Recent Advances in Immunotherapy in Metastatic NSCLC.
Recent Advances in Immunotherapy in Metastatic NSCLC.
复制标题
转移性NSCLC免疫疗法的最新进展。
DOI:
10.3389/fonc.2016.00239
复制
发表时间:
2016
影响因子:
4.7
通讯作者:
Boumber Y
中科院分区:
文献类型:
--
作者:
Bansal P;Osman D;Gan GN;Simon GR;Boumber Y
Non-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of programed death receptor-1 inhibitors, such as nivolumab and pembrolizumab. Here, we review promising immunotherapeutic approaches in metastatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, and immunotherapy combinations with other drugs. With advent of immunotherapy, therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further expand life expectancy in metastatic lung cancer.
登录
查看更多内容
影响因子:
16.6
作者:
Koyama S;Akbay EA;Li YY;Herter-Sprie GS;Buczkowski KA;Richards WG;Gandhi L;Redig AJ;Rodig SJ;Asahina H;Jones RE;Kulkarni MM;Kuraguchi M;Palakurthi S;Fecci PE;Johnson BE;Janne PA;Engelman JA;Gangadharan SP;Costa DB;Freeman GJ;Bueno R;Hodi FS;Dranoff G;Wong KK;Hammerman PS
通讯作者:
Hammerman PS
DOI:
10.1200/edbook_am.2013.33.e295
发表时间:
2013-01-01
期刊:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
影响因子:
--
作者:
Juergens, Rosalyn A;Rudin, Charles M
通讯作者:
Rudin, Charles M
影响因子:
4.4
作者:
Chen, X;Doffek, K;Shilyansky, J
通讯作者:
Shilyansky, J
影响因子:
50.5
作者:
Champiat, S.;Lambotte, O.;Marabelle, A.
通讯作者:
Marabelle, A.
影响因子:
105.7
作者:
BURNET, M
通讯作者:
BURNET, M